Poxel S.A. (0RA2.L)

1,6000 0,0000 (0,00%) Alla chiusura: 08:29AM BST

Poxel S.A.

Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 4 37 37 20 10
https://www.poxelpharma.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 15

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.	Co-Founder, CEO & Director	412,64k	N/D	N/D
Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D.	Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing Operations	N/D	N/D	N/D
Dr. Pascale Fouqueray-Grellier M.D., Ph.D.	Co-Founder and Executive VP of Clinical Development & Regulatory Affairs	N/D	N/D	N/D
Dr. Sophie Hallakou-Bozec Ph.D.	Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication	N/D	N/D	N/D
Arthur Rouille	Investor Relations Officer	N/D	N/D	N/D
Mr. Quentin Durand	Executive VP, Chief Legal Officer & Head of Corporate Social Responsibility	N/D	N/D	N/D
Ms. Sylvie Bertrand	Vice President of Human Resources	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Governance aziendale

L'ISS Governance QualityScore di Poxel S.A. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 9; diritti degli azionisti: 4; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.